Stem cell infusion shows promise for Hard-to-Treat GVHD

NCT ID NCT00284986

Completed Disease control Sponsor: Mesoblast, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a stem cell product called Prochymal in 11 patients with severe graft-versus-host disease (GVHD) that did not improve with standard treatments. The goal was to see if the infusion could reduce or resolve GVHD symptoms by day 28. The study measured complete or partial response and tracked side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prochymal (adult human mesenchymal stem cells)
What this could lead to: If it works, this could offer a new treatment option for patients with severe graft-versus-host disease that hasn't responded to other therapies.
What could go wrong: This is a very small, early-phase study with only 11 participants, so results may not apply to everyone. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27708, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.